Please use this identifier to cite or link to this item:
Title: Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes : an approach for improved oral pharmacokinetics of Sorafenib
Authors: Muhammad Adeeb Khan
Shaukat Ali
Venkatraman, Subbu S.
Muhammad Farhan Sohail
Muhammad Ovais
Abida Raza
Keywords: Engineering::Materials
Issue Date: 2018
Source: Muhammad Adeeb Khan, Shaukat Ali, Venkatraman, S. S., Muhammad Farhan Sohail, Muhammad Ovais, Abida Raza. (2018). Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes : an approach for improved oral pharmacokinetics of Sorafenib. International Journal of Pharmaceutics, 542(1-2), 196-204. doi:10.1016/j.ijpharm.2018.03.023
Journal: International Journal of Pharmaceutics
Abstract: Sorafenib (SFN), a hydrophobic anticancer drug, has several limitations predominantly poor aqueous solubility and hepatic first-pass effect, limiting its oral delivery that results into several other complications. Present study aims to develop Sorafenib loaded polymersomes using poly butadiene block poly ethylene oxide (PB-b-PEO), an amphiphilic co-block polymer. Prior to drug loading, critical aggregate concentration (CAC) of polymer was calculated for stable formulation synthesis. The developed SFN loaded PB-b-PEO polymersomes (SFN-PB-b-PEO, test formulation) characterized by DLS and cryo-TEM showed particle size 282 nm, polydispersity (PDI) of less than 0.29 and membrane thickness of about 20 nm. SFN-PB-b-PEO polymersomes demonstrated encapsulation efficiency of 71% and showed sustained drug release up to 144 h. Formulation remained stable for 3 months in suspension form. In vitro cytotoxicity against HepG2 cells showed 1.7 folds improved toxicity compared to SFN suspension. In addition, oral administration of SFN-PB-b-PEO polymersomes in BALB/c mice showed increased Cmax and AUC0-96 by 1.7 and 2.77-fold respectively (p < 0.05) compared to those of SFN suspension (reference formulation). Findings suggest that the SFN-PB-b-PEO polymersomes can be a potential candidate for oral delivery of SFN.
ISSN: 0378-5173
DOI: 10.1016/j.ijpharm.2018.03.023
Rights: © 2018 Elsevier B.V. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:MSE Journal Articles

Citations 20

Updated on Feb 5, 2023

Web of ScienceTM
Citations 20

Updated on Jan 30, 2023

Page view(s)

Updated on Feb 5, 2023

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.